Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on Feb 23, 2023 8:49am
90 Views
Post# 35300297

RE:Expectations for next Q results are low

RE:Expectations for next Q results are lowI think those two things have been true for a while now lol.. low expectations and impatience. 

There will likely be some mark to market losses in the funds ending 2022, which will probably rebound in Q1. We'll see how March plays out.

Operations should be pretty steady. Not expecting anything major in Q4. I'd like to see that Exelon is pretty well fully integrated and they are done with GBT integration as well. 

Assuming similar cashflow generation, they should have a higher cash balance excluding the new debt deal. Probably spending a little more than half on share buybacks. 

There will be opportunities to allocate cash this year, and with the last deals more or less up and running, more time for management to allocate to new deals.
<< Previous
Bullboard Posts
Next >>